1. **(ORIGINAL)** A compound of the formula:



(I)

wherein

ring A represents an aromatic ring optionally having substituents;

B, Y and Ya are the same or different and each represents a bond or a spacer having a main chain of 1 to 6 atoms;

R^1 and R^2 are the same or different and each represents a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, or R^1 and R^2, together with the adjacent nitrogen atom, form a nitrogen-containing heterocyclic ring optionally having substituents, or R^1 is linked with ring A together with the adjacent nitrogen atom and B to form a 5- to 7-membered nitrogen-containing heterocyclic ring;

R^3 represents a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents;

R^4 and R^5 are the same or different and each represents a hydrogen atom or a hydrocarbon group optionally having

substituents, or R^4 and R^5, together with the adjacent carbon atom, form a ring optionally having substituents;

R^6 represents an indolyl group optionally having substituents; and

Z and Za are the same or different and each represents a hydrogen atom, a halogen atom or a cyclic group optionally having substituents; or a salt thereof.

2. **(ORIGINAL)** A prodrug of the compound according to claim 1 or a salt thereof.

3. **(ORIGINAL)** The compound according to claim 1, wherein R^3 is a hydrogen atom or a C_{1-6} alkyl optionally having substituents.

4. **(ORIGINAL)** The compound according to claim 1, wherein one of R^4 and R^5 is a hydrogen atom, and the other is a C_{1-6} alkyl optionally having substituents.

5. **(ORIGINAL)** The compound according to claim 1, wherein Z is a cyclic group optionally having substituents.

6. **(ORIGINAL)** The compound according to claim 5, wherein the cyclic group is piperidinyl or piperazinyl.

7. **(ORIGINAL)** The compound according to claim 5, wherein Z is piperidinyl or piperazinyl, each of which is substituted by a

group of the formula: -Yd-Ara wherein Yd represents a bond or a spacer having a main chain of 1 to 6 atoms, and Ara represents a monocyclic group optionally having substituents.

8. **(ORIGINAL)** The compound according to claim 1, wherein Ya is a bond, and Za is a hydrogen atom.

9. **(ORIGINAL)** The compound according to claim 1, wherein B is a C_{1-6} alkylene.

10. **(ORIGINAL)** The compound according to claim 1, wherein the aromatic ring represented by ring A is benzene.

11. **(ORIGINAL)** The compound according to claim 1, wherein R^1 and R^2 are C_{1-6} alkyl.

12. **(ORIGINAL)** The compound according to claim 1, wherein Y is -CO-.

13. **(ORIGINAL)** The compound according to claim 1, which is

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-((methylamino)carbonyl)phenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(2-methylphenyl)-1-piperidinecarboxamide;

N-((1R,2S)-1-(((2-((dimethylamino)carbonyl)-5-((dimethylamino)methyl)phenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(4-fluorophenyl)-1-piperidinecarboxamide;

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-methoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(4-fluoro-2-methylphenyl)-3-oxo-1-piperazinecarboxamide;

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-methoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(2-methylphenyl)-1-piperazinecarboxamide;

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-ethoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-(4-fluorophenyl)-1-piperazinecarboxamide; or

N-((1R,2S)-1-(((5-((dimethylamino)methyl)-2-ethoxyphenyl)amino)carbonyl)-2-(1H-indol-3-yl)propyl)-4-phenyl-1-piperidinecarboxamide.

14. **(ORIGINAL)** A pharmaceutical preparation comprising the compound according to claim 1, a salt thereof or a prodrug thereof.

15. **(ORIGINAL)** The pharmaceutical preparation according to claim 14, which is a somatostatin receptor binding inhibitor.

16. **(ORIGINAL)** The pharmaceutical preparation according to claim 15, which is a somatostatin subtype 2 receptor binding inhibitor.

17. **(ORIGINAL)** The pharmaceutical preparation according to claim 14, which is a somatostatin receptor agonist.

18. **(ORIGINAL)** The pharmaceutical preparation according to claim 17, which is a somatostatin subtype 2 receptor agonist.

19. **(ORIGINAL)** The pharmaceutical preparation according to claim 14, which is a prophylactic or therapeutic agent for diabetes or diabetic complications.

20. **(ORIGINAL)** The pharmaceutical preparation according to claim 14, which is a prophylactic or therapeutic agent for obesity.

21. **(CANCELED)**

22. **(ORIGINAL)** A method for inhibiting somatostatin receptor binding in a mammal, which comprises administering to the mammal an effective amount of the compound according to claim 1, a salt thereof or a prodrug thereof.

23. **(CANCELED)**

24. **(ORIGINAL)** A method for preventing or treating diabetes or diabetic complications in a mammal, which comprises administering to the mammal an effective amount of the compound according to claim 1, a salt thereof or a prodrug thereof.

25. **(CANCELED)**

26. **(ORIGINAL)** A method for preventing or treating obesity in a mammal, which comprises administering to the mammal an effective amount of the compound according to claim 1, a salt thereof or a prodrug thereof.

27. **(ORIGINAL)** A method for producing a compound of claim 1 or a salt thereof, which comprises reacting a compound of the formula:



wherein

Y represents a bond or a spacer having a main chain of 1 to 6 atoms;

R^4 and R^5 are the same or different, and each represents a hydrogen atom or a hydrocarbon group optionally having substituents, or R^4 and R^5, together with the adjacent carbon atom, form a ring optionally having substituents;

R^6 represents an indolyl group optionally having substituents;

Z represents a hydrogen atom, a halogen atom or a cyclic group optionally having substituents; or a salt thereof, with a compound of the formula:



wherein

ring A represents an aromatic ring optionally having substituents;

B represents a bond or a spacer having a main chain of 1 to 6 atoms;

R^1 and R^2 are the same or different, and each represents a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, or R^1 and R^2, together with the adjacent nitrogen atom, form a nitrogen-containing heterocyclic ring optionally having substituents, or R^1 is linked with ring A together with the adjacent nitrogen atom and B to form a 5- to 7-membered nitrogen-containing heterocyclic ring;

R^3 represents a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents; or a salt thereof to give a compound of the formula:



wherein

each symbol is as defined above; or a salt thereof, and optionally reacting the compound or a salt thereof with a compound of the formula: L^4-Ya-Za wherein L^4 represents a leaving group; Ya represents a bond or a spacer having a main chain of 1 to 6 atoms; Za represents a hydrogen atom, a halogen atom or a cyclic group optionally having substituents; or a salt thereof.

28. **(ORIGINAL)** A compound of the formula:



wherein

Y represents a bond or a spacer having a main chain of 1 to 6 atoms;

R^4 and R^5 are the same or different, and each represents a hydrogen atom or a hydrocarbon group optionally having substituents, or R^4 and R^5, together with the adjacent carbon atom, form a ring optionally having substituents;

R^6 represents an indolyl group optionally having substituents;

Zb represents piperidinyl or piperazinyl, each of which is substituted by a group of the formula: -Yd-Ara wherein Yd represents a bond or a spacer having a main chain of 1 to 6 atoms, and Ara represents a monocyclic group optionally having substituents; or a salt thereof.